Norovirus GII

A positive norovirus GII stool result can help explain sudden vomiting and watery diarrhea, but it needs to fit your symptoms and when they started. Norovirus spreads through contaminated food, water, surfaces, and contact with other people. The result alone cannot identify where you caught it.

Testing is most useful when identifying the cause could change the evaluation of severe or persistent illness, or help investigate an outbreak. Many brief, uncomplicated episodes are diagnosed from symptoms without laboratory testing.

What This Stool Result Measures

This test looks for norovirus genogroup II RNA in stool using qPCR. RNA carries the virus's genetic instructions. For an RNA virus, PCR testing includes a step that converts RNA into DNA, followed by repeated copying of a selected sequence so it can be detected.

Molecular stool testing is an established way to detect norovirus. A positive result identifies viral genetic material in the sample; it does not directly measure infectious virus or prove that the virus is still multiplying.

Using the amount detected to predict complications or decide when someone is no longer contagious remains exploratory. There is no universal stool viral-load scale that reliably makes those decisions for an individual.

The listed unit, CFU/g stool, needs particular care. CFU refers to colony-forming units used in culture, whereas this test detects viral RNA. Norovirus qPCR results are not counts of colonies. Research measurements expressed as genome copies cannot be treated as equivalent to this reporting unit.

GII Versus GI

GI and GII are genetic groups within norovirus, and both commonly infect people. GII accounts for most human norovirus infections. In a Brazilian study of stool samples collected during 2017–2018, about nine in ten norovirus detections were GII. That proportion varies by population, place, and year.

Several studies found higher stool RNA concentrations with GII than with GI, though the size of the difference varied. These studies used their own assays and RNA standards. Their measurements do not establish how to interpret a number reported in CFU/g stool.

GII.4 and GII.17 are different types within GII. Brazilian surveillance documented GII.17[P17] replacing GII.4 Sydney[P16] as the predominant type among sequenced samples in 2024. A smaller Thai study during 2021–2023 also found frequent GII.17 infections, including GII.17[P16]. These findings describe particular places and periods; they do not identify the strain in your sample.

A GII qPCR result generally does not distinguish these types. Identifying a lineage requires additional genetic analysis, usually for surveillance or outbreak investigation.

Why a Positive Result Can Outlast Illness

Norovirus RNA can remain detectable after vomiting and diarrhea stop, and some people test positive without having symptoms. In one Japanese study, 2.5% of symptom-free adults had detectable norovirus. That figure combined GI and GII and sits at the low end. A meta-analysis pooling studies worldwide put symptom-free detection at about 7% in general surveillance, and rates are higher still among people exposed during outbreaks.

An analysis of a human challenge study estimated average stool RNA shedding of about three to four weeks. The volunteers received GI.1, a different norovirus group, so those results provide context for prolonged detection without establishing a GII-specific timetable.

A positive result during a compatible illness supports norovirus as the cause. A positive result after recovery, or alongside another possible cause of diarrhea, needs a different interpretation. Persistent RNA detection alone cannot establish the cause of ongoing symptoms or how readily you could transmit infection.

What Viral Load Research Shows

Higher stool RNA levels have been associated with more severe illness in some studies. In a study of 152 people with cancer, higher loads were associated with about five and a half times the odds of severe symptoms in the authors' analysis. The study included both GI and GII and used its own RNA quantification method.

In a Brazilian pediatric study, about one in five children with norovirus-positive stool also had viral RNA detected in serum. Those children had higher stool RNA levels and longer hospital stays. This was an observational association, not proof that a stool value independently predicts how long a child will need hospital care. This stool test does not assess viral RNA in blood.

Cycle threshold, or Ct, is the number of copying cycles needed for a PCR signal to become detectable. Within the same assay and comparable sample preparation, a lower Ct generally indicates more starting viral RNA.

Research has explored Ct values as a way to distinguish illness-causing infection from incidental detection. But symptomatic and symptom-free people overlap, and results depend on the assay, strain, age, and sample timing. A study using data from the United States and Latin America found that Ct-based classification performed poorly for individual diagnosis. There is no transferable Ct cutoff that proves norovirus caused your symptoms.

Severe and Persistent Illness

Young children, older adults, and people with weakened immune systems are more vulnerable to dehydration and other complications. Recent US data also link heart disease and having several chronic conditions to a higher chance of hospitalization after norovirus illness. The amount of RNA reported in stool is not a substitute for assessing fluid loss, ability to drink, urine output, and underlying health.

A study of more than 23,000 US veterans found that a positive norovirus stool test was associated with about twice the adjusted risk of death during the next three days compared with a negative test. Fewer than 1% of positive test episodes were followed by death during that interval. The study involved people seeking medical care and did not report this association separately for GII.

The mortality difference was no longer statistically clear at one week or one month. These findings describe an early association in a medically vulnerable population. They do not establish that norovirus has no later effects, and they do not make a stool RNA concentration a mortality prediction tool.

Persistent infection is a separate problem in people with substantial immune suppression. A hospital study linked intensive immunosuppressive treatment to prolonged RNA shedding. NIH surveillance documented infections lasting months to years in people with inherited or acquired immune defects, sometimes with chronic diarrhea and poor nutrient absorption.

Strain differences also appear in outbreak research. A review of 843 outbreaks found that GII.4 outbreaks had roughly nine times the hospitalization rate and three times the death rate of outbreaks involving other genotypes after adjustment for measured factors. These were comparisons between outbreaks, and a GII-only result does not establish that you have GII.4.

Some people develop persistent bowel symptoms after an acute infection has resolved. A prospective study following an outbreak attributed to norovirus found an increase in irritable bowel symptoms during the following months. Ongoing symptoms therefore do not necessarily mean that the virus remains the cause.

When Results Can Be Misleading

False negatives can occur when too little viral RNA reaches the reaction, sample handling damages RNA, substances in stool interfere with PCR, or a strain's genetic sequence is poorly matched to the assay. Contamination or nonspecific reactions can produce false positives. The exact performance depends on the laboratory's assay; the label qPCR alone does not establish its sensitivity, specificity, or target sequence.

Specific commercial panels have had documented problems. In a study of specimens collected from US veterans during 2018–2023, about a quarter of BioFire FilmArray norovirus-positive results were not confirmed by the study's reference methods. A pediatric study also found substantial disagreement when positives from that panel were retested. Those findings concern that platform and combined norovirus detection, and cannot be assigned as the false-positive rate of this GII test.

Assays can also differ in which strains they detect well. A comparison involving children with gastroenteritis found that a laboratory-developed assay detected GII.2 more sensitively than the Luminex xTAG panel. Neither a dedicated assay nor a broad panel is automatically accurate for every strain.

Results from different laboratories may reflect different extraction procedures, genetic targets, calibration standards, and reporting rules. Numerical values and Ct results should not be compared across methods as if they were interchangeable. Even a correctly detected positive needs to be interpreted alongside symptoms, recent illness, and other findings.